{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:01:29Z","timestamp":1789934489053,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,29]],"date-time":"2011-10-29T00:00:00Z","timestamp":1319846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00125-011-2357-4","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T21:41:24Z","timestamp":1319838084000},"page":"36-45","source":"Crossref","is-referenced-by-count":56,"title":["Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial"],"prefix":"10.1007","volume":"55","author":[{"name":"The TIDE Trial Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,29]]},"reference":[{"key":"2357_CR1","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","volume":"303","author":"OJ Phung","year":"2010","unstructured":"Phung OJ, Scholle JM, Talwar M, Coleman CI (2010) Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303:1410\u20131418","journal-title":"JAMA"},{"key":"2357_CR2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","volume":"368","author":"HC Gerstein","year":"2006","unstructured":"Gerstein HC, Yusuf S, Bosch J et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096\u20131105","journal-title":"Lancet"},{"key":"2357_CR3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104\u20131115","journal-title":"N Engl J Med"},{"key":"2357_CR4","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427\u20132443","journal-title":"N Engl J Med"},{"key":"2357_CR5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0149-2918(04)90068-9","volume":"26","author":"M Tan","year":"2004","unstructured":"Tan M, Johns D, Gonzalez GG et al (2004) Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 26:680\u2013693","journal-title":"Clin Ther"},{"key":"2357_CR6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1524-6175.2005.04784.x","volume":"8","author":"R Qayyum","year":"2006","unstructured":"Qayyum R, Adomaityte J (2006) A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens (Greenwich) 8:19\u201328","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2357_CR7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.ajkd.2009.11.013","volume":"55","author":"PA Sarafidis","year":"2010","unstructured":"Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN (2010) Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis 55:835\u2013847","journal-title":"Am J Kidney Dis"},{"key":"2357_CR8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2337\/dc07-1868","volume":"31","author":"GR Dagenais","year":"2008","unstructured":"Dagenais GR, Gerstein HC, Holman R et al (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31:1007\u20131014","journal-title":"Diabetes Care"},{"key":"2357_CR9","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2215\/CJN.09291010","volume":"6","author":"JM Lachin","year":"2011","unstructured":"Lachin JM, Viberti G, Zinman B et al (2011) Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 6:1032\u20131040","journal-title":"Clin J Am Soc Nephrol"},{"key":"2357_CR10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00592-008-0054-7","volume":"46","author":"SK Vijay","year":"2009","unstructured":"Vijay SK, Mishra M, Kumar H, Tripathi K (2009) Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol 46:27\u201333","journal-title":"Acta Diabetol"},{"key":"2357_CR11","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc06-1854","volume":"30","author":"DM Riche","year":"2007","unstructured":"Riche DM, Valderrama R, Henyan NN (2007) Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care 30:384\u2013388","journal-title":"Diabetes Care"},{"key":"2357_CR12","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.12.072","volume":"53","author":"EM Lonn","year":"2009","unstructured":"Lonn EM, Gerstein HC, Sheridan P et al (2009) Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol 53:2028\u20132035","journal-title":"J Am Coll Cardiol"},{"key":"2357_CR13","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","volume":"296","author":"T Mazzone","year":"2006","unstructured":"Mazzone T, Meyer PM, Feinstein SB et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296:2572\u20132581","journal-title":"JAMA"},{"key":"2357_CR14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1161\/01.ATV.0000124890.40436.77","volume":"24","author":"JS Sidhu","year":"2004","unstructured":"Sidhu JS, Kaposzta Z, Markus HS, Kaski JC (2004) Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24:930\u2013934","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2357_CR15","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2337\/diacare.27.11.2654","volume":"27","author":"D Choi","year":"2004","unstructured":"Choi D, Kim SK, Choi SH et al (2004) Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27:2654\u20132660","journal-title":"Diabetes Care"},{"key":"2357_CR16","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561\u20131573","journal-title":"JAMA"},{"key":"2357_CR17","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/diacare.28.7.1680","volume":"28","author":"SE Inzucchi","year":"2005","unstructured":"Inzucchi SE, Masoudi FA, Wang Y et al (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680\u20131689","journal-title":"Diabetes Care"},{"key":"2357_CR18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","volume":"111","author":"FA Masoudi","year":"2005","unstructured":"Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583\u2013590","journal-title":"Circulation"},{"key":"2357_CR19","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"RL Frye","year":"2009","unstructured":"Frye RL, August P, Brooks MM et al (2009) A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360:2503\u20132515","journal-title":"N Engl J Med"},{"key":"2357_CR20","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"PD Home","year":"2009","unstructured":"Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125\u20132135","journal-title":"Lancet"},{"key":"2357_CR21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279\u20131289","journal-title":"Lancet"},{"key":"2357_CR22","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","volume":"121","author":"S Kaul","year":"2010","unstructured":"Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH (2010) Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 121:1868\u20131877","journal-title":"Circulation"},{"key":"2357_CR23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(05)67504-6","volume":"366","author":"H Yki-Jarvinen","year":"2005","unstructured":"Yki-Jarvinen H (2005) The PROactive Study: some answers, many questions. Lancet 366:1241\u20131242","journal-title":"Lancet"},{"key":"2357_CR24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/bmj.331.7520.836","volume":"331","author":"N Freemantle","year":"2005","unstructured":"Freemantle N (2005) How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ 331:836\u2013838","journal-title":"BMJ"},{"key":"2357_CR25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","volume":"370","author":"RM Lago","year":"2007","unstructured":"Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370:1129\u20131136","journal-title":"Lancet"},{"key":"2357_CR26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijcard.2009.01.064","volume":"143","author":"E Mannucci","year":"2010","unstructured":"Mannucci E, Monami M, Di BM et al (2010) Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 143:135\u2013140","journal-title":"Int J Cardiol"},{"key":"2357_CR27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MJT.0b013e318167180c","volume":"15","author":"N Nagajothi","year":"2008","unstructured":"Nagajothi N, Adigopula S, Balamuthusamy S et al (2008) Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. Am J Ther 15:506\u2013511","journal-title":"Am J Ther"},{"key":"2357_CR28","doi-asserted-by":"crossref","unstructured":"Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH (2006) Pioglitazone for type 2 diabetes mellitus Cochrane Database Syst Rev 4:CD006060. doi: 10.1002\/14651858.CD006060.pub2","DOI":"10.1002\/14651858.CD006060.pub2"},{"key":"2357_CR29","doi-asserted-by":"crossref","unstructured":"Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH (2007) Rosiglitazone for type 2 diabetes mellitus Cochrane Database Syst Rev 3:CD006063. doi: 10.1002\/14651858.CD006063.pub2","DOI":"10.1002\/14651858.CD006063.pub2"},{"key":"2357_CR30","unstructured":"Food and Drug Administration briefing document: 13\u201314 July 2010 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (2011). Available from www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/ucm191113.htm . Accessed 25 April 2011"},{"key":"2357_CR31","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.2337\/diacare.27.12.2813","volume":"27","author":"R Scragg","year":"2004","unstructured":"Scragg R, Sowers M, Bell C (2004) Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27:2813\u20132818","journal-title":"Diabetes Care"},{"key":"2357_CR32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ecl.2010.02.016","volume":"39","author":"MF Holick","year":"2010","unstructured":"Holick MF (2010) Vitamin D: extraskeletal health. Endocrinol Metab Clin North Am 39:381\u2013400","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2357_CR33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2337\/diacare.29.03.06.dc05-2148","volume":"29","author":"M Cigolini","year":"2006","unstructured":"Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher G (2006) Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care 29:722\u2013724","journal-title":"Diabetes Care"},{"key":"2357_CR34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/CIRCULATIONAHA.107.706127","volume":"117","author":"TJ Wang","year":"2008","unstructured":"Wang TJ, Pencina MJ, Booth SL et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503\u2013511","journal-title":"Circulation"},{"key":"2357_CR35","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1001\/archinte.167.16.1730","volume":"167","author":"P Autier","year":"2007","unstructured":"Autier P, Gandini S (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167:1730\u20131737","journal-title":"Arch Intern Med"},{"key":"2357_CR36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/CIRCULATIONAHA.106.673491","volume":"115","author":"J Hsia","year":"2007","unstructured":"Hsia J, Heiss G, Ren H et al (2007) Calcium\/vitamin D supplementation and cardiovascular events. Circulation 115:846\u2013854","journal-title":"Circulation"},{"key":"2357_CR37","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMoa055222","volume":"354","author":"J Wactawski-Wende","year":"2006","unstructured":"Wactawski-Wende J, Kotchen JM, Anderson GL et al (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684\u2013696","journal-title":"N Engl J Med"},{"key":"2357_CR38","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/jnci\/djn360","volume":"100","author":"RT Chlebowski","year":"2008","unstructured":"Chlebowski RT, Johnson KC, Kooperberg C et al (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581\u20131591","journal-title":"J Natl Cancer Inst"},{"key":"2357_CR39","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ajcn\/85.6.1586","volume":"85","author":"JM Lappe","year":"2007","unstructured":"Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586\u20131591","journal-title":"Am J Clin Nutr"},{"key":"2357_CR40","unstructured":"Harris G (2010) Research ties diabetes drug to heart woes. New York Times, 19 February 2010"},{"key":"2357_CR41","volume-title":"Staff report on GlaxoSmithKline and the diabetes drug Avandia 111-41","author":"M Baucus","year":"2010","unstructured":"Baucus M, Grassley C (2010) Staff report on GlaxoSmithKline and the diabetes drug Avandia 111-41. US Government Printing Office, Washington"},{"key":"2357_CR42","unstructured":"Food and Drug Administration FDA Drug Safety Communication: ongoing review of Avandia (rosiglitazone) and cardiovascular safety (2010). Available from www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm201418.htm . Accessed 9 May 2011"},{"key":"2357_CR43","unstructured":"Mundy A, Corbett Dooren J (2010) FDA weighs halting avandia safety study. Wall Street Journal 19 April 2010"},{"key":"2357_CR44","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1373\/clinchem.2007.097402","volume":"54","author":"C Weykamp","year":"2008","unstructured":"Weykamp C, John WG, Mosca A et al (2008) The IFCC reference measurement system for HbA1c: a 6-year progress report. Clin Chem 54:240\u2013248","journal-title":"Clin Chem"},{"key":"2357_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2010.05.019","volume":"160","author":"HC Gerstein","year":"2010","unstructured":"Gerstein HC, Yusuf S (2010) Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: implications for the evaluation of antidiabetic drugs. Am Heart J 160:1\u20132","journal-title":"Am Heart J"},{"key":"2357_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/med\/9780199204854.003.020303_update_002","volume-title":"Oxford textbook of medicine","author":"C Baigent","year":"2010","unstructured":"Baigent C, Peto R, Gray R, Parish S, Collins R (2010) Large-scale randomized evidence: trials and meta-analyses of trials. In: Warrell DA, Cox TM, Firth JD (eds) Oxford textbook of medicine, 5th edn. Oxford University Press, Oxford, pp 31\u201345","edition":"5"},{"key":"2357_CR47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/sim.4780030421","volume":"3","author":"S Yusuf","year":"1984","unstructured":"Yusuf S, Collins R, Peto R (1984) Why do we need some large, simple randomized trials? Stat Med 3:409\u2013422","journal-title":"Stat Med"},{"key":"2357_CR48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","volume":"324","author":"DS Echt","year":"1991","unstructured":"Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo\u2014The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781\u2013788","journal-title":"N Engl J Med"},{"key":"2357_CR49","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"Anonymous","year":"1991","unstructured":"Anonymous (1991) Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension Final results of the Systolic Hypertension in the Elderly Program (SHEP) SHEP Cooperative Research Group. JAMA 265:3255\u20133264","journal-title":"JAMA"},{"key":"2357_CR50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/jama.287.7.883","volume":"287","author":"JM Foody","year":"2002","unstructured":"Foody JM, Farrell MH, Krumholz HM (2002) Beta-blocker therapy in heart failure: scientific review. JAMA 287:883\u2013889","journal-title":"JAMA"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-011-2357-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-011-2357-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-011-2357-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T18:13:29Z","timestamp":1593195209000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-011-2357-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,29]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["2357"],"URL":"https:\/\/doi.org\/10.1007\/s00125-011-2357-4","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,29]]}}}